TERMINALIA ARJUNA: POSSIBLE TREATMENT FOR SICKLE CELL ANAEMIA & POTENT BIOFUEL A REVIEW ARTICLE

The review “Terminalia arjuna: The possible treatment for sickle cell anaemia & potent biofuel” explores various studies on the Terminalia arjuna plant, emphasising its potential therapeutic applications for sickle cell anaemia (SCA) and various cardiovascular disorders. Key findings highlight the anti-sickling properties of 5-Hydroxymethylfurfural, a primary bioactive compound found in leaf galls formed in response to insect attacks from Trioza fletcheri. Research indicates that extracts from Terminalia arjuna have significant anti-sickling effects; however, further clinical studies and safety evaluations are needed to confirm their therapeutic efficacy and standardisation. Additionally, the review discusses the traditional use of Arjuna bark decoction in the Indian subcontinent for managing angina, hypertension, and heart failure. Recent findings reveal its anti-ischemic and antioxidant properties due to beneficial phytoconstituents like triterpenoids and flavonoids. While promising for ischemic cardiomyopathy, the long-term safety of Terminalia arjuna requires further investigation, particularly in the context of coronary prevention.